Sign up to get the latest stories and insights delivered to your inbox – free, every day.
NZX and ASX-listed cancer diagnostics company Pacific Edge has been granted a halt in trading of its shares while an expert panel in the US considers coverage for some of its CXbladder tests, which were included in the American Urological Association microhaematuria guideline.
Novitas, the firm’s Medicare Administrative Contractor is holding a Contract Advisory Committee meeting with urologists at midday Friday NZ time, when the company’s shares would normally be trading.
The public meeting will discuss the use of urine-based biomarkers in patients that present with microhematuria. Because the meetings are generally held ahead of developing new or substantially revised medical policy as a draft Local Coverage Determination, the content of the meeting could indicate whether the MAC will develop a draft LCD to support Medicare reimbursement of Cxbladder tests.
Pacific Edge plans to release a statement about the CAC meeting before the market opens on Monday.